Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury

Pinelopi P. Kapitsinou, Jonathan Jaffe, Mark Michael, Christina E. Swan, Kevin J. Duffy, Connie L. Erickson-Miller, Volker H. Haase

Research output: Contribution to journalArticlepeer-review

55 Scopus citations

Abstract

Acute kidney injury (AKI) due to ischemia is an important contributor to the progression of chronic kidney disease (CKD). Key mediators of cellular adaptation to hypoxia are oxygen-sensitive hypoxia-inducible factors (HIF), which are regulated by prolyl-4-hydroxylase domain (PHD)-containing dioxygenases. While activation of HIF protects from ischemic cell death, HIF has been shown to promote fibrosis in experimental models of CKD. The impact of HIF activation on AKI-induced fibrosis has not been defined. Here, we investigated the role of pharmacologic HIF activation in AKI-associated fibrosis and inflammation. We found that pharmacologic inhibition of HIF prolyl hydroxylation before AKI ameliorated fibrosis and prevented anemia, while inhibition of HIF prolyl hydroxylation in the early recovery phase of AKI did not affect short- or long-term clinical outcome. Therefore, preischemic targeting of the PHD/HIF pathway represents an effective therapeutic strategy for the prevention of CKD resulting from AKI, and it warrants further investigation in clinical trials.

Original languageEnglish (US)
Pages (from-to)F1172-F1179
JournalAmerican Journal of Physiology - Renal Physiology
Volume302
Issue number9
DOIs
StatePublished - May 1 2012

Keywords

  • HIF prolyl-4-hydroxylases
  • Hypoxia-inducible factor

ASJC Scopus subject areas

  • Physiology
  • Urology

Fingerprint Dive into the research topics of 'Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury'. Together they form a unique fingerprint.

Cite this